Obsidian Therapeutics, Inc.
OBX Nasdaq
SEC CIK 2130606
Follow Obsidian Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$50.7M
−77.9% vs same quarter last year
EPS, diluted
−$1.23
+91.7% vs same quarter last year
Operating cash flow
−$36.7M
−73.3% vs same quarter last year
Source: SEC XBRL filings · latest filing